The global autoimmune disease diagnostics market size was valued at USD 6.78 billion in 2025 and is projected to grow from USD 7.29 billion in 2026 to USD 13.02 billion by 2034, registering a CAGR of 7.52% during the forecast period from 2026 to 2034. North America dominated the autoimmune disease diagnostics market with a market share of 39.5% in 2025.
The autoimmune disease diagnostic market is expanding steadily as the prevalence of autoimmune disorders such as rheumatoid arthritis, lupus, and multiple sclerosis rises worldwide. Increased awareness among healthcare providers and patients about early detection fuels demand for precise diagnostic tools. In October 2025, Abbott received FDA clearance for a new multiplex autoimmune panel detecting 12 autoantibodies simultaneously, improving diagnostic breadth and efficiency.
Advancements in fully automated immunoassay analyzers and AI‑assisted interpretation tools enhance sensitivity and reduce misdiagnosis. Strategic collaborations between diagnostic companies and research institutions strengthen R&D, while emerging AI‑based models help analyze complex immune signatures. Expansion of healthcare infrastructure in emerging regions and public health initiatives promoting autoimmune screening further support growth. However, challenges like high test costs and limited insurance coverage slow adoption, highlighting the need for a rapid diagnostics solution.
Download a Free Sample To learn more about this report,
Use of Liquid Biopsy Approaches for Autoimmune Disease Monitoring
The need for less invasive biomarkers is encouraging research into circulating cell-free DNA and other blood-based signals for autoimmune disease monitoring. In systemic lupus erythematosus, cfDNA has been investigated as a biomarker because its levels and molecular characteristics can reflect immune activity and disease-related processes. This approach could support more frequent disease monitoring and personalized management, although further validation and standardization are needed before routine clinical use.
Development of Personalized Autoimmune Diagnostic Panels
The clinical diversity of autoimmune diseases is increasing the need for diagnostic approaches that capture multiple biological features rather than relying on a single marker. Research in systemic sclerosis shows that combining autoantibodies, vascular markers, and immunomodulatory mediators can create pathophysiological profiles that distinguish different patient groups. Such personalized panels can support more precise disease classification and may improve the identification of patients with different progression or treatment-response patterns.
Aging Population and Rare Autoimmune Diagnosis Drive Market
The larger older population creates a broader patient base requiring evaluation for chronic and autoimmune conditions. WHO reports that the global population aged 60 years and older is projected to reach 1.4 billion by 2030 and 2.1 billion by 2050, compared with about 1 billion in 2020. For example, older patients with persistent joint pain, fatigue, or inflammation may undergo rheumatoid factor, anti-CCP, or ANA testing during clinical evaluation. This demographic shift supports sustained diagnostic volumes and encourages laboratories to maintain autoimmune testing capacity.
The diagnostic complexity of rare autoimmune disorders creates a need for specialized testing that can distinguish uncommon conditions from diseases with similar clinical symptoms. NIH estimates that approximately 25–30 million people in the U.S. are affected collectively by rare diseases, highlighting the scale of patients who may require specialized diagnostic evaluation. For example, patients with suspected rare autoimmune disorders may require disease-specific autoantibody testing alongside clinical and laboratory assessment. This need supports demand for specialized assays and encourages diagnostic laboratories to provide testing for less common autoimmune conditions.
Laboratory Infrastructure and Reimbursement Limitations Restrain Market Expansion
Limited access to advanced laboratory infrastructure can restrict the availability of specialized autoimmune testing, automated immunoassay platforms, and confirmatory diagnostic equipment. WHO reports that approximately 47% of the world's population lacks access to basic laboratory diagnostics, highlighting persistent gaps in diagnostic capacity. These infrastructure gaps can increase referral needs and testing delays, limiting diagnostic access and slowing market adoption.
Reimbursement and coverage limitations can make specialized autoimmune disease diagnostic tests less affordable for patients and healthcare providers. The U.S. Centers for Medicare & Medicaid Services notes that Medicare coverage depends on whether diagnostic laboratory tests meet applicable coverage requirements, with specific national and local coverage policies influencing payment. These coverage constraints can discourage the use of additional or advanced testing and reduce demand for autoimmune disease diagnostics.
Diagnostic Partnerships and Automated Immunoassay Platforms Offers Growth Opportunities
Diagnostic companies, rheumatology centers, hospitals, and clinical laboratories can collaborate on autoimmune testing programs and specialized diagnostic services. Thermo Fisher Scientific’s Phadia Laboratory Systems support automated allergy and autoimmune testing, while its ImmunoDiagnostics business serves laboratories and healthcare providers, creating revenue through testing contracts, instruments, and recurring reagent sales.
Diagnostic laboratories, hospitals, and immunoassay manufacturers can use automated systems for antibody detection and standardized autoimmune testing. Werfen’s bio-flash system provides automated chemiluminescent immunoassay testing and includes autoimmune assays, creating revenue through analyzers, reagents, and recurring consumable sales.
Patient Sample Limitations and Multiplex Development Complexity Hinders Growth
Developing and validating autoimmune diagnostic tests requires diverse samples linked to reliable clinical diagnoses and disease characteristics. The NIH's National Institute of Allergy and Infectious Diseases notes that autoimmune research is challenged by the heterogeneity of autoimmune diseases and the need for well-characterized biological specimens to support research and biomarker development. These challenges can increase R&D timelines and make it harder for companies to demonstrate test performance.
New autoimmune diagnostics increasingly aim to evaluate multiple antibodies, proteins, and inflammatory markers simultaneously. The U.S. FDA notes that multiplex assays can involve multiple analytes and require appropriate analytical validation to establish performance characteristics for the intended use. Higher validation and optimization requirements can increase development costs and delay product launches.
The assay kits & consumables segment accounted for a 65.8% share in 2025 and is expected to grow at a CAGR of 9.2% during the forecast period 2026-2034, driven by increasing demand for accurate autoimmune disease testing, growing adoption of immunoassays and diagnostic kits, and rising prevalence of autoimmune disorders. the increasing need for early diagnosis, expanding diagnostic testing volumes, and continuous development of advanced assay technologies further strengthen the segment’s dominant position in the autoimmune disease diagnostics market.
The instruments segment supports autoimmune disease diagnosis through laboratory analyzers, testing equipment, and automated diagnostic platforms. the increasing adoption of automated laboratory systems, growing demand for high-throughput testing, and rising integration of advanced diagnostic technologies continue to support demand for instruments.
Request Customizationto receive a tailored report.
The rheumatoid arthritis segment accounted for a share of 24.6% in 2025, owing to the high prevalence of rheumatoid arthritis, increasing demand for early and accurate diagnosis, and widespread use of diagnostic testing for disease monitoring. the growing awareness of autoimmune disorders, increasing adoption of laboratory-based testing, and need for regular disease assessment further strengthen the segment’s dominant position in the autoimmune disease diagnostics market.
The inflammatory bowel disease segment is expected to grow at a CAGR of 9.4% during the forecast period 2026-2034, driven by increasing prevalence of inflammatory bowel conditions, growing demand for early diagnosis and disease monitoring, and rising adoption of advanced diagnostic technologies. the increasing awareness of gastrointestinal autoimmune conditions, expansion of diagnostic testing, and development of more sensitive and specific diagnostic methods further support growth of the segment. the systemic lupus erythematosus segment contributes through diagnostic testing for disease identification and monitoring, while autoimmune thyroid diseases support demand through routine thyroid and antibody testing. type 1 diabetes, scleroderma, vasculitis, and other diseases continue to contribute to market demand through specialized diagnostic requirements.
The immunoassays segment accounted for a share of 38.7% in 2025 due to their widespread use in autoimmune disease diagnosis, established clinical adoption, and ability to detect disease-specific antibodies and biomarkers. the increasing demand for accurate laboratory testing, growing prevalence of autoimmune disorders, and broad availability of immunoassay-based diagnostic solutions further strengthen the segment’s dominant position in the autoimmune disease diagnostics market.
The point-of-care testing segment is expected to grow at a CAGR of 10.1% during the forecast period 2026-2034, fueled by increasing demand for rapid diagnostic results, growing adoption of decentralized testing, and rising need for convenient and accessible autoimmune disease screening. the development of portable diagnostic technologies, increasing use of rapid testing in clinical settings, and growing emphasis on early disease detection further support growth of the segment. the indirect immunofluorescence segment supports antibody detection and disease identification, while multiplex assays enable simultaneous analysis of multiple biomarkers. molecular diagnostics contributes through advanced biomarker and genetic testing, while other technology includes additional diagnostic approaches used across autoimmune disease testing.
The clinical laboratories segment accounted for a 42.8% share in 2025 and is expected to grow at a CAGR of 9.1% during the forecast period 2026-2034, driven by increasing demand for specialized autoimmune disease testing, growing diagnostic volumes, and rising adoption of advanced laboratory technologies. the availability of comprehensive testing capabilities, increasing need for accurate disease monitoring, and expansion of clinical laboratory networks further strengthen the segment’s dominant position in the autoimmune disease diagnostics market.
The hospitals & clinics segment supports autoimmune disease diagnosis through routine testing, specialist consultations, and patient monitoring, while the academic & research institutes segment contributes through research on disease biomarkers, diagnostic methods, and emerging technologies. the other end users segment includes additional healthcare and research settings that utilize autoimmune disease diagnostic solutions.
Speak to an Analystto discuss market opportunities.
The North America autoimmune disease diagnostics market accounted for the largest regional share of 39.5% in 2025, fueled by advanced diagnostic infrastructure, high awareness of autoimmune disorders, and increasing adoption of advanced diagnostic technologies. The U.S. autoimmune disease diagnostics market is supported by a substantial burden of autoimmune conditions and extensive laboratory testing infrastructure. The CDC estimates that approximately 204,000 people in the U.S. have systemic lupus erythematosus, while CDC reports that healthcare professionals order more than 14 billion laboratory tests annually in the U.S., with test results used for medical decisions.
The Canada autoimmune disease diagnostics market is fueled by the continued diagnosis and monitoring of autoimmune conditions, including rheumatoid arthritis and systemic lupus erythematosus. Health Canada identifies rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and other conditions as autoimmune diseases, while Statistics Canada notes that rheumatoid arthritis diagnosis involves symptom assessment, physical examination, laboratory tests, and X-rays, supporting the need for diagnostic testing in autoimmune disease management.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific autoimmune disease diagnostics market is expected to grow at a CAGR of 10.6% during the forecast period 2026-2034, showcasing the fastest-growing regional market, driven by rising healthcare expenditure, increasing awareness of autoimmune diseases, and expanding access to diagnostic services. In Japan, the Japan autoimmune disease diagnostics market is supported by the ministry of health, labour and welfare’s 2026 updates to diagnostic criteria and clinical investigation forms for designated intractable diseases, including systemic lupus erythematosus, systemic sclerosis, Sjögren syndrome, and antiphospholipid syndrome.
In China China autoimmune disease diagnostics market is due to new 2026 clinical laboratory standards covering immunological testing and reference intervals for immunoglobulins and complement components, with implementation scheduled for november 2026, strengthening standardization of laboratory testing relevant to autoimmune disease diagnosis. In South Korea autoimmune disease diagnostics market is owing to the national disease control agency’s updated rare disease information system, which provides diagnostic guidance for autoimmune conditions including systemic lupus erythematosus, mixed connective tissue disease, antiphospholipid syndrome, and juvenile idiopathic arthritis, including autoantibody and other laboratory testing. In India a autoimmune disease diagnostics market is supported by standardized in-vitro diagnostic evaluation protocols developed by the Indian Council of Medical Research and CDSCO, for which the government invited comments in august 2026, supporting greater consistency in the evaluation of diagnostic technologies.
The Europe autoimmune disease diagnostics market accounted for a regional share of 28.4% in 2025, driven by established healthcare systems, increasing demand for early disease detection, and growing adoption of advanced laboratory diagnostics. In the U.K. autoimmune disease diagnostics market, NHS pathology services continue to provide specialized autoimmune testing, including antinuclear antibodies, anti-CCP antibodies, anti-thyroid peroxidase antibodies, and disease-specific antibody assays. Updated laboratory information in 2026 shows continued use of immunology testing for diagnosing and investigating autoimmune conditions, supporting demand for specialized diagnostic assays.
In the Germany autoimmune disease diagnostics market, the country's laboratory and diagnostic infrastructure continues to support specialized testing and clinical research. The Robert Koch Institute maintains a nationwide network of 21 National Reference Centres and 38 Consultant Laboratories for specialized diagnostics and surveillance, with the current appointment period covering 2026–2028, supporting Germany's broader diagnostic infrastructure. Meanwhile, the France autoimmune disease diagnostics market is due to established autoimmune testing, with Inserm stating that autoimmune disease diagnosis relies on clinical and biological assessments and may include specific biomarker testing for autoantibodies such as anti-DNA, ANCA, CCP, and rheumatoid factor. The French Ministry of Health is also strengthening diagnostic capabilities through the fourth national plan for rare diseases, including expanded use of genomic testing and efforts to reduce diagnostic delays, supporting the broader development of advanced diagnostic technologies.
The Middle East & Africa autoimmune disease diagnostics market is expected to grow at a CAGR of 7.6% during the forecast period 2026-2034, driven by improving healthcare infrastructure, rising investment in diagnostic services, and increasing focus on early detection of autoimmune disorders. The UAE autoimmune disease diagnostics market is expected to benefit from the country’s growing focus on precision medicine, genomics, and early disease detection. In 2026, the Department of Health – Abu Dhabi’s healthcare research and innovation fund identified omics and precision medicine, including genomics, transcriptomics, proteomics, metabolomics, and microbiome research, as priority areas. The Abu Dhabi Biobank also connects biological samples with genomic, lifestyle, and clinical data to support earlier detection and personalized care, strengthening the ecosystem for advanced diagnostic testing for immune-mediated and autoimmune conditions.
The Africa autoimmune disease diagnostics market is expected to benefit from continued investments in laboratory capacity, diagnostic quality, and medical-product regulation. In August 2026, African health ministers endorsed the Regional Strategy on Regulation of Medical Products in the African Region 2026–2035, which covers diagnostics and aims to strengthen regulatory systems and access to quality-assured health products. WHO also reported that all Member States in the African Region now have sequencing capacity, while laboratory assessments, quality-assurance initiatives, and expanded diagnostic and genomic surveillance activities continue across the region.
The autoimmune disease diagnostics market is moderately fragmented, with diagnostic companies, biotechnology firms, pharmaceutical companies, clinical laboratories, medical device manufacturers, and specialized autoimmune testing providers competing across immunoassays, antibody testing, molecular diagnostics, and other diagnostic applications. Established players compete primarily on diagnostic accuracy, assay sensitivity and specificity, test reliability, technological innovation, clinical validation, product portfolio breadth, research and development capabilities, regulatory compliance, automation, and global distribution networks, with leading players such as hoffmann-la roche ltd, abbott laboratories, siemens healthineers ag, thermo fisher scientific inc., and bio-rad laboratories, inc. estimated to account for approximately 50% of the global market based on their diagnostic portfolios, technological capabilities, clinical testing expertise, geographic presence, and competitive positioning.
Emerging and regional players within the autoimmune disease diagnostics market ecosystem compete through cost-effective testing solutions, rapid diagnostic technologies, specialized biomarker assays, point-of-care platforms, customized solutions, flexible workflows, localized support, and application-specific products to address evolving autoimmune disease diagnostic requirements and strengthen their market presence. these players also focus on developing specialized testing platforms, improving diagnostic accessibility, and expanding biomarker detection capabilities to differentiate their offerings and broaden their market reach.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Organ Preservation Market Size, Share, Growth, Analysis, Report, 2034
Bacteriophage Market Size, Share, Growth, Analysis, 2034
Epigenetics Market Size, Share, Growth, Analysis, Report, 2034
Biobanking Market Size, Share, Growth, 2034
Cell Therapy Manufacturing Market Size, Share, Growth, 2034
Clinical Oncology Next Generation Sequencing Market Size, 2034
We are featured on:
sales@straitsresearch.com